Development of a standardised method to recommend protective measures to handle hazardous drugs in hospitals

European Journal of Hospital Pharmacy

Volumn 20, Issue 2, 2013, Pages 100-105

  Kaestli, Laure Zoé ^a,b   Fonzo Christe, Caroline ^a   Bonfillon, Chantal ^a   Desmeules, Jules ^a,b   Bonnabry, Pascal ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ALGORITHM; ARTICLE; CARCINOGENICITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; HUMAN; MUTAGENICITY; OCCUPATIONAL HAZARD; PROTECTIVE CLOTHING; QUALITY CONTROL PROCEDURES; REPRODUCTION; RISK; TERATOGENICITY; TOXICITY TESTING;

EID: 84875737090     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2012-000222     Document Type: Article

References (21)

1. Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 2008;26:103-19.
2. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988;30:984-7.
3. Hemminki K, Kyyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthesic gases, cytostatic drugs, and potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 1985;39:141-7.
4. Selevan SG, Lindbohm ML, Hornung RW, et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985;313:1173-8.
5. Anon. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 2006;63:1172-91.
6. Mason HJ, Blair S, Sams C, et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 2005;49:603-10.
7. Centers for Disease Control and Prevention. NIOSH Alert. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Cincinnati: NIOSH, Publication No. 2004-165, 2004. http://www.cdc.gov/niosh/docs/2004-165/(accessed 14 Dec 2011).
8. Centers for Disease Control and Prevention. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010. DHHS (NIOSH) Publication No. 2010-167. http://www.cdc.gov/niosh/docs/2010-167/pdfs/2010-167.pdf (accessed 14 Dec 2011).
9. University HealthSystem Consortium (UHC). UHC consensus statement: model hazardous drug safety plan for institutions. Am J Health-Syst Pharm 2010;67:1545-6.
10. Jost M, Rüegger M, Liechti B, et al. Sécurité dans l'emploi des cytostatiques. 3rd edn. Luzern: SUVAPro, 2004.
11. Compendium suisse des medicaments. Bâle: Documed 2011. http://www. kompendium.ch/(accessed 22 Nov 2012).
12. McDiarmid MA, Condon M. Organizational safety culture/climate and worker compliance with hazardous drug guidelines: lessons from the blood-borne pathogen experience. J Occup Environ Med 2005;47:740-9.
13. Gambrell J, Moore S. Assessing workplace compliance with handling of antineoplastic agents. Clin J Oncol Nurs 2006;10:473-7.
14. International Agency for Research on Cancer. IARC's monographs on the evaluation of carcinogenics risks to humans. List of all agents evaluated to date (listed by CAS numbers). http://monographs.iarc.fr/ENG/Monographs/vol100A/index.php (accessed 14 Dec 2011).
15. Reprotox®, Drugdex®. Micromedex healthcare series, 1974-2008. Thomson Healthcare. http://www.thomsonhc.com/home/dispatch (accessed 14 Dec 2011).
16. Anon. Risk and safety phrases. Wikipedia. http://en.wikipedia.org/wiki/Risk_and_Safety_Statements (accessed 14 Dec 2011).
17. Anon. NIOSH response to public comments. 2009. http://www.cdc.gov/niosh/review/public/105-a/pdfs/ResponsetoPublic.pdf (accessed 14 Dec 2011).
18. Alemany C, Kaestli LZ, Fonzo-Christe C, et al. Université Genève. 2005. http://pharmacie.hug-ge.ch/ens/travmaitrise/2005_ca_eval_risq_manip_antico_monocl.pdf (accessed 14 Dec 2011).
19. Pigneret-Bernard S, Saint-Lorant G, Divanon F. Safety of monoclonal antibodies for the technician: myth or realityAbout a survey of professional practice. J Pharm Clin 2008;27:227-33.
20. Massoomi F, Neff B, Pick A. Implementation of a safety program for handling hazardous drugs in a community hospital. Am J Health-Syst Pharm 2008;65:861-5.
21. Rousselin X. Les médicaments cytostatiques en milieu de soins. 1. Toxicité et risques professionnels. 2. Recommandations pour la prévention des risques professionnels. Dossier médico-technique TC36 INRS, Paris, 1991. http://mtriay.free. fr/Textes_officiels/tc36.pdf (accessed 14 Dec 2011).